Agios Pharmaceuticals Inc (STU:8AP)
€ 45.8 0.8 (1.78%) Market Cap: 2.49 Bil Enterprise Value: 1.59 Bil PE Ratio: 4.05 PB Ratio: 1.61 GF Score: 28/100

Agios Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference Transcript

Sep 12, 2023 / 11:30AM GMT
Release Date Price: €25.2 (+4.13%)
Matthew Kelsey Harrison
Morgan Stanley, Research Division - Executive Director

Great. Good morning, everybody. Thanks for joining us for Day 2. I'm Matthew Harrison in Investment Banking at Morgan Stanley. Very pleased to have Agios with us for the next session. Just quickly before we get started, I have to read disclosure statement. Please note that important research disclosures can be found at morganstanley.com/researchdisclosures. Really pleased to have Brian and Sarah with us this morning. Brian, let you introduce yourselves, and then we can jump into it.

Brian M. Goff
Agios Pharmaceuticals, Inc. - CEO & Director

Sure. Thanks a lot, Matthew, and thanks, everybody, for listening in. I'm Brian Goff, I'm the CEO of Agios and I joined in the middle of last year, 2022.

Sarah Gheuens
Agios Pharmaceuticals, Inc. - Chief Medical Officer and Head of Research & Development

Hi, everyone. I'm Sarah Gheuens. I'm the Head of R&D and Chief Medical Officer, and I joined Agios in the end of 2019.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot